Authors

Latest:

Dr. Kirson Discusses the LUNAR Study in Advanced NSCLC

Eilon Kirson, MD, PhD, chief medical officer, Novocure, discusses the LUNAR study in advanced non–small cell lung cancer.

Elaine Chang, MD

Latest:

Emerging Adulthood: From Adolescent to Attending Physician

Faced with a persistent question from her teenage years, Elaine Chang, MD, may have come up with an answer.

Elaine R. Mardis, PhD

Latest:

Elaine Mardis on Sensitivity to Aromatase Inhibitors

Elaine Mardis, from the Genome Institute at Washington University School of Medicine, on Sensitivity to Aromatase Inhibitors

Elaine Shum, MD

Elaine Shum, MD is an Assistant Professor of Medicine at NYU Perlmutter Cancer Center in New York.

Latest:

Dr Shum on Evolving First-Line Treatment Approaches for EGFR-Mutant NSCLC

Elaine Shum, MD, discusses questions that remain regarding the first-line treatment paradigm for patients with EGFR-mutant non–small cell lung cancer.

Eleanor M. Walker, MD

Latest:

Dr. Walker on the Use of Radiation Therapy in Patients With Breast Cancer

Eleanor M. Walker, MD, senior staff physician, division director, Breast Services in the Department of Radiation Oncology, Henry Ford Cancer Institute, discusses the use of radiation therapy in patients with breast cancer.

Electra D. Paskett, PhD

Latest:

Electra D. Paskett, PhD, on Cervical Cancer Screening

Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, discusses the use of vinegar as a cervical cancer screening tool in the U.S.

Eleftheria Kalogera, MD, MSc

Latest:

Dr. Kalogera on Bowel Preparation Following Minimally Invasive or Open Hysterectomies

Eleftheria Kalogera, MD, MSc, instructor in Obstetrics and Gynecology, fellow in Gynecologic Oncology, in the department of Obstetrics and Gynecology, at Mayo Clinic College of Medicine, discusses the controversial topic of bowel preparation following minimally invasive or open hysterectomies.

Eleftherios P. Mamounas, MD

Latest:

Dr Mamounas on Surgical De-Escalation Strategies in HER2+ Breast Cancers

Terry P. Mamounas, MD, discusses surgical de-escalation strategies in the treatment of patients with HER2-positive breast cancer.

Eleftherios P. Mamounas, MD, University Florida

Eleftherios (Terry) P. Mamounas, MD

Latest:

Dr Mamounas on Key Advancements in the Use of Locoregional Therapy in Breast Cancer

Terry P. Mamounas, MD, discusses key advancements in the use of locoregional therapy for patients with breast cancer.

Elena Lukina, MD

Latest:

Dr. Lukina Discusses Timely Gaucher Disease Diagnosis

Dr. Elena Lukina Discusses Timely Gaucher Disease Diagnosis

Elena S. Ratner, MD, Yale University School of Medicine

Eleni Andreopoulou, MD

Latest:

Dr. Andreopoulou on the Impact of Immunotherapy in TNBC

Eleni Andreopoulou, MD, associate professor of clinical medicine, Weill Cornell Medical College, associate attending physician, NewYork-Presbyterian Hospital, discusses shifts in the treatment paradigm of metastatic triple-negative breast cancer (TNBC) and the impact immunotherapy has had in the field.

Eleonora Teplinsky, MD

Latest:

Antibody-Drug Conjugates and T-DM1

Human epidermal growth factor receptor 2 (HER2)-positive disease accounts for 20% to 25% of breast cancers, as represented by amplification of the HER2 gene and/or HER2 protein overexpression

Elham Nasri, MD

Latest:

Dr. Nasri on the Role of p16 and p21 as Predictive Biomarkers in Osteosarcoma

Elham Nasri, MD, discusses the role of p16 and p21 as predictive biomarkers in patients with osteosarcoma.

Eli L. Diamond, MD

Latest:

Dr. Diamond on the Ability to Test Urine for BRAF Mutations

Eli L. Diamond, MD, neurologist, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis that examined the detection of BRAF mutations in urine and plasma cell-free DNA in patients with Langerhans Cell Histiocytosis(LCH) and Erdheim-Chester Disease (ECD) who have a BRAFV600E mutation

Elias J. Jabbour, MD, MD Anderson

Elias Jabbour, MD, is a professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Latest:

ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.

Elias Jabbour, MD

Elias Jabbour, MD, is a professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Latest:

Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD

Drs Aldoss and Jabbour discuss an analysis of PhALLCON that support the use of ponatinib monotherapy after TKI/chemotherapy treatment in Ph-positive ALL.

Elias Jabbour, MD, MD Anderson Cancer Center

Elias Jabbour, MD, is a professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Latest:

Ongoing Research Efforts and More in Ph+ Acute Lymphoblastic Leukemia

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss ongoing research efforts in the treatment paradigm of Philadelphia chromosome–positive acute lymphoblastic leukemia.